Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Sebi has approved new disclosure standards for Related Party Transactions to boost transparency and investor protection. The ...

HER2, a HER2-targeted immunotherapy, with plans for FDA submission following promising Phase 2b data in osteosarcoma.

Vertiv (NYSE:VRT – Get Free Report) had its price target dropped by analysts at Barclays from $142.00 to $131.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an ...